Terralpha harnesses ADVA TeraFlex ™ for 600G transport throughout France
ADVA (FSE: ADV) today announced that Terralpha has deployed its FSP 3000 TeraFlex™ terminal to transport data at speeds up to 600Gbit/s between cities across France. The solution enables Terralpha – the new service provider arm of France’s SNCF railway group – to use its spare fiber capacity to offer low-latency, ultra-high-speed connectivity to customers. Now, enterprises, mobile network operators and government institutions can leverage flexible, highly reliable services for edge computing and 5G applications. What’s more, Terralpha’s network will enable homes and businesses in many underserved areas to access next-generation broadband and mobile connectivity. The new solution also features ADVA’s FSP 3000 OLS, flexgrid multi-degree ROADMs, its ALM fiber monitoring technology and its Ensemble Controller network management and control solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005706/en/
ADVA’s TeraFlex™ technology is helping Terralpha to drive 600G connectivity throughout France. (Photo: Business Wire)
“With around 20,000km of fiber deployed alongside our railway infrastructure, we knew we were in a unique position to offer super-fast connectivity right across France. What we needed was a transport solution with the capacity, flexibility and scale to match our ambitions and a partner we could trust. In ADVA, we have a European technology provider with a wealth of experience and an excellent track record for success,” said Gabriel Chenevoy, CEO of Terralpha. “The ADVA team has worked with us to deliver a solution that maximizes the value of our existing network and empowers us to provide our customers with a new level of bandwidth capacity and service quality. Our backbone infrastructure will be key to closing the digital divide by delivering high-speed services in a highly efficient and sustainable way to around 100 tier 3 cities within two years. The performance of ADVA’s equipment combined with our straight and diverse routes has enabled us to reduce actual latencies between major cities in France from 10% to 40%, supporting new latency-sensitive applications.”
The ADVA FSP 3000 TeraFlex™ terminal is specifically designed to inject enormous capacity into deployed networks without operators having to spend significant amounts on overhauling their infrastructure. With its software-defined fractional QAM modulation and adaptive baud rate capabilities, the low-power 1RU terminal is now ensuring optimal spectrum utilization in Terralpha’s transport system. The network is managed by ADVA’s Ensemble Controller, which supports programmatic SDN control, further improving efficiency by reducing troublesome and time-consuming manual processes. The infrastructure is also continuously assured by ADVA’s ALM fiber monitoring technology with precise fault localization from Ensemble Fiber Director. This enables Terralpha’s maintenance teams to quickly detect and pinpoint any degradation in the fiber plant and resolve issues before services are affected.
“We’re helping Terralpha to unlock the full value of its fiber assets. By harnessing our technology and the expertise of our engineers, Terralpha can take advantage of its vast network architecture to bring reliable, low-latency services at unprecedented speeds to homes, businesses and service provider customers in every corner of France,” commented Hartmut Müller-Leitloff, SVP of sales, EMEA at ADVA. “One of the keys to the success of this project has been our close collaboration with the Terralpha team to make sure the new solution meets their exact requirements. That’s helped us deliver a turnkey solution that works seamlessly with Terralpha’s existing network to provide optimal performance over every single link. With our scalable technology and continuing support, there’s no limit to what Terralpha can achieve.”
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Incorporated in 2021, Terralpha, a 100% subsidiary of SNCF Réseau, offers Ultra High Speed data transport services. Its DNA “Ultra High Speed for all territories” is supported by an ambition to deploy Ultra High Speed and high reliability points of presence throughout France. The choice of architecture and transmission equipment, of European origin, enables to create circuits between cities at speeds of 100Gb/s to 600Gb/s at very low latency.
Terralpha’s mission is to ensure the trusted routing of data traffic through fully owned active and passive infrastructure. Additionally, and in order to facilitate the development of regional data centers, Terralpha offers a range of hosting solutions called ”Digital Tiles” to host the equipment necessary for the storage and the processing of information locally. Each of these “Digital Tiles” has a dual fiber connection to the Terralpha network, and to the public networks to meet the strategic requirements of data centers. www.terralpha.fr
ADVA Optical Networking SE, Munich, Germany
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
For ADVA press:
t +44 1904 699 358
For ADVA investors:
t +49 89 890 665 854
For Terralpha press:
t +33 1 84 21 15 07
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma26.5.2022 23:25:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination
Ipsen: ASCO 2022: New Cabometyx ® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer26.5.2022 23:00:00 CEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor (TKI), Cabometyx® (cabozantinib), across a range of cancer types at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2022) to be held on 3-7 June. Data presentations will include findings in metastatic non-small cell lung cancer (NSCLC), as well as established indications of advanced renal cell carcinoma and radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). These data show that the therapeutic potential of Cabometyx as a key treatment option in a broad range of tumors is continuing to be realized. Updated outcomes from the multicenter Phase Ib COSMIC-021 trial evaluating the combination of Cabometyx plus atezolizumab in an expanded patient population in metastatic NSCLC demonstrate encouraging clinical activity with manageable toxicity in people previously treated with an immune checkpoint inhib
New Better Dispensing Videos from Nordson EFD Explain Jetting Technology and How to Choose the Right Solution26.5.2022 19:00:00 CEST | Press release
Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces a new Better Dispensing™ How-To Video series. These three highly educational videos presented by EFD application specialist, Tom Muccino, provide best practices for choosing between contact dispensing and non-contact (jet) dispensing, and how to select the best jetting valve for a manufacturing application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510006079/en/ xQR41 Series MicroDot™ needle valve (left) and PICO Pµlse XP jet valve (right). (Photo: Business Wire) “One of the main differences is that with jetting, your valve never touches the surface of the part. Instead, your fluid “flies” or “jets” out of the valve, which is above the part,” Muccino explains in the first video. “This makes jetting perfect for fragile or complex parts.” Nordson EFD provides a wide range of contact and non-contact (jet
Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA26.5.2022 18:17:00 CEST | Press release
On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio). “Partnering with Deebio in June 2021 was a huge milestone for the pharmaceutical compounding industry as it allowed us to secure and stabilize the supply of high quality Thyroid Powder for the US market,” said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca. “After going to market, we immediately realized that the demand for Thyroid Powder extended outside of our usual distribution channels to compounding pharmacies,” continued Danopoulos. “And we had the capacity to upscale supply to make this critical ingredient accessible to various markets, chan
Merck to Present Latest Research From Oncology Portfolio at ASCO 202226.5.2022 18:00:00 CEST | Press release
Merck, a leading science and technology company, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. Data encompass Company-sponsored, investigator-sponsored, and external collaboration studies. Abstracts to be shared at the meeting include data for the Company’s licensed medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab), and its oncology pipeline. The presentations span key tumor types including advanced urothelial carcinoma (UC), advanced renal cell carcinoma (RCC), metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer (CRC), and head and neck cancer (SCCHN). “We look forward to coming together with the scientific community at ASCO 2022, where we will share the latest data from our portfolio, which demonstrate our determination to make a real difference in the lives of